New Parkinson's drug offers hope for local sufferers

Innovative new drug to fight Parkinson's disease is now available in local hospitals.

Innovative drug Azilect, developed by Danish drug firm Lundbeck in collaboration with Teva, will enter local hospitals to help treat Shanghai patients with Parkinson's disease (PD).

So far Azilect is available in Huadong Hospital, Xinhua Hospital, Shanghai No.6 Hospital, Zhongshan Hospital and Huashan Hospital at 39.8 yuan (US$6) per box.

Azilect is an inhibitor of monoamine oxidase B, used in combination therapy to treat symptoms in early Parkinson's disease, or as an adjunct therapy in more advanced cases. 

It was formally approved by the China Food and Drug Administration (CFDA) in June 2017. Azilect is now being sold in more than 50 countries and regions around the world, with millions of PD patients using it.

Research data shows that combination therapy can significantly improve exercise and non-motor symptoms of PD patients, while in combined treatment it can improve the effect of levodopa treatment and control symptoms.

"As a world leader in psychiatry and neurology, Lundbeck is devoted to developing innovative medicines that can help millions of Parkinsons' patients and their caregivers around the world to lead better lives," said Soren Kjeld Kristensen, president and general manager of Lundbeck China. "We are delighted to now offer Azilect to Chinese physicians and patients."  

Parkinson's disease is a type of movement disorder which is considered the third killer of elderly people, following cancer and cardio-cerebrovascular diseases. 

In China, it is assumed that more than 2.5 million people are suffering from the disease, and a certain amount of them remain unaware.

Special Reports